Natural anti-obesity agents

Bulletin of Faculty of Pharmacy, Cairo University

Volumn 52, Issue 2, 2014, Pages 269-284

  Mohamed, Gamal A ^a   Ibrahim, Sabrin R M ^b   Elkhayat, Ehab S ^a   El Dine, Riham Salah ^c  

^a Al Azhar University   (Egypt)

^b Assiut University   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

Mechanism; Natural products; Obesity; Physical

Indexed keywords

ALKALOID; AMFEPRAMONE; ANOREXIGENIC AGENT; ANTIOBESITY AGENT; ASTAXANTHIN; DIURETIC AGENT; FLUOXETINE; GINGEROL; GLYCYRRHIZIC ACID; IODINE; KRILL OIL; LAXATIVE; NATURAL PRODUCT; OIL; ORGANOSULFUR DERIVATIVE; PECTIN; PHENTERMINE; PHYTOSTEROL; PLANT MEDICINAL PRODUCT; POLYPHENOL; POLYUNSATURATED FATTY ACID; RIMONABANT; SHOGAOL; SIBUTRAMINE; STEVIOSIDE; TERPENOID; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 1; UNINDEXED DRUG;

BARIATRIC SURGERY; BODY MASS; CELERY; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENERGY EXPENDITURE; GARCINIA CAMBOGIA; HEART DISEASE; HIBISCUS SABDARIFFA; HUMAN; HYPERTENSION; LIPID METABOLISM; LIPOGENESIS; LIPOLYSIS; LUNG DISEASE; MENTAL DISEASE; METABOLIC SYNDROME X; NEOPLASM; NEUROLOGIC DISEASE; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PEANUT; PHYSICAL ACTIVITY; PINEAPPLE; REVIEW; SEDENTARY LIFESTYLE; SOCIAL ASPECT; TEA; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT CONTROL;

EID: 85029485230     PISSN: 11100931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bfopcu.2014.05.001     Document Type: Review

References (185)

1. World Health Organization. Obesity: preventing and managing the global epidemic report of a WHO consultation on obesity. WHO: Geneva, Switzerland; 1998.
2. Popkin B.M. The world is fat: the fads, trends, policies, and products that are fattening the human race 2009, Avery Trade/Penguin Group, New York.
3. Singla P., Bardoloi A., Parkash A.A. Metabolic effects of obesity: a review. World J Diabetes 2010, 1:76-88.
4. Derdemezis C.S., Voulgari P.V., Drosos A.A., Kiortsis D.N. Obesity, adipose tissue and rheumatoid arthritis: coincidence or more complex relationship?. Clin Exp Rheumatol 2011, 29:712-727.
5. Withrow D., Alter D.A. The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. Obes Rev 2011, 12:131-141.
6. Popkin B.M., Kim S., Rusev E.R., Du S., Zizza C. Measuring the full economic costs of diet, physical activity and obesity-related chronic diseases. Obes Rev 2006, 7:271-293.
7. Timar R, Obezitatea adultului, Serban V, Babes PA. Clinica Medicala. Teorie si practica, Editura de Vest, Timisoara; 1999, p. 83-198.
8. Aronne L.J. Classification of obesity and assessment of obesity-related health risks. Obes Res 2002, 10(2):S105-S115.
9. Ordovás J.M., Shen J. Gene-environment interactions and susceptibility to metabolic syndrome and other chronic diseases. J Periodontol 2008, 799:1508-1513.
10. International Obesity Task Force [IOTF]. /. http://www.iotf.org.
11. Marti A., Martinez-González M.A., Martinez J.A. Interaction between genes and lifestyle factors on obesity. Proc Nutr Soc 2008, 67:1-8.
12. Pérusse L., Bouchard C. Gene-diet interactions in obesity. Am Soc Clin Nutr 2000, 72:1285S-1290S.
13. World Health Organization. Global strategy on diet, physical activity and health. WHO: Geneva, Switzerland; 2007.
14. Santos A.P., Rogero M.M., Bastos D.H. Edible plants, their secondary metabolites and antiobesogenic potential. Recent Pat Food Nutr Agric 2010, 2:195-212.
15. Rayalam S., Della-Fera M.A., Baile C.A. Phytochemicals and regulation of the adipocyte life cycle. J Nutr Biochem 2008, 19:717-726.
16. Liu R.H. Health benefits of fruit and vegetables are from additive and synergistic combinations of phytochemicals. Am J Clin Nutr 2003, 78:S517-S520.
17. Online Etymology Dictionary: Obesity. Douglas Harper.
18. Physical Status: The Use and Interpretation of Anthropometry. WHO Technical Report Series 854:9.
19. Brown J.E., Potter J.D., Jacobs D.R., Kopher R.A., Rourke M.J., et al. Maternal waist-to-hip ratio as a predictor of newborn size: results of the diana project. Epidemiology 1996, 7:62-66.
20. Lau D.C., Douketis J.D., Morrison K.M., Hramiak I.M., Sharma A.M. Obesity canada clinical practice guidelines expert panel. CMAJ 2007, 176:S1-S13.
21. Bleich S., Cutler D., Murray C., Adams A. Why is the developed world obese?. Annu Rev Public Health 2008, 29:273-295.
22. James W.P. The fundamental drivers of the obesity epidemic. Obes Rev 2008, 9(1):6-13.
23. Keith S.W., Redden D.T., Katzmarzyk P.T. Putative contributors to the secular increase in obesity: exploring the roads less traveled. Int J Obes 2006, 30:1585-1594.
24. Flegal K.M., Carroll M.D., Ogden C.L., Johnson C.L. Prevalence and trends in obesity among U.S. adults. JAMA 2002, 288:1723-1727.
25. Ness-Abramof R., Apovian C.M. Diet modification for treatment and prevention of obesity. Endocrine 2006, 29:5-9.
26. Salmon J., Timperio A. Prevalence, trends and environmental influences on child and youth physical activity. Med Sport Sci 2007, 50:183-199.
27. Loos R.J., Bouchard C. FTO: the first gene contributing to common forms of human obesity. Obes Rev 2008, 9:246-250.
28. Farooqi I.S., Keogh J.M., Yeo G.S.H., Lank E.J., Cheetham T., et al. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. Engl J Med 2003, 348:1085-1095.
29. Nothen M.M., Cichon S., Hemmer S., Hebebrand J., Remschmidt H., et al. Human dopamine D4 receptor gene: frequent occurrence of a null allele and observation of homozygosity. Hum Mol Genet 1994, 3:2207-2212.
30. Ristow M., Muller-Wieland D., Pfeiffer A., Krone W., Kahn C.R. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 1998, 339:953-959.
31. Campfield L.A., Smith F.J., Rosenbaum M., Hirsch J. Human eating: evidence for a physiological basis using a modified paradigm. Neurosci Biobehav Rev 1996, 20:133-137.
32. Rosén T., Bosaeus I., Tölli J., Lindstedt G., Bengtsson B.A. Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiency. Clin Endocrinol 1993, 38:63-71.
33. Haslam D.W., James W.P. Obesity. Lancet 2005, 366:1197-1209.
34. Chiles C., Van Wattum P.J. Psychiatric aspects of the obesity crisis. Psychiatr Times 2010, 27:47-51.
35. Yach D., Stuckler D., Brownell K.D. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med 2006, 12:62-66.
36. Sobal J., Stunkard A.J. Socioeconomic status and obesity: a review of the literature. Psychol Bull 1989, 105:260-275.
37. Chiolero A., Faeh D., Paccaud F., Cornuz J. Consequences of smoking for body weight, body fat distribution, and insulin resistance. Am J Clin Nutr 2008, 87:801-809.
38. Di-Baise J.K., Zhang H., Crowell M.D., Krajmalnik-Brown R., Decker G.A., et al. Mayo Clinic proceedings. Gut microbiota and its possible relationship with obesity. Mayo Clin 2008, 83:460-469.
39. Palou M., Sanchez J., Rodriguez A.M., Priego T., Pico C., et al. Induction of NPY/AgRP orexigenic peptide expression in rat hypothalamus is an early event in fasting: relationship with circulating leptin, insulin and glucose. Cell Physiol Biochem 2009, 23:115-124.
40. Hamann A., Matthaei S. Regulation of energy balance by leptin. Exp Clin Endocrinol Diabetes 1996, 104:293-300.
41. Flier J.S. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004, 116(2):337-350.
42. Wren A.M., Bloom S.R. Gut hormones and appetite control. Gastroenterology 2007, 132(6):2116-2130.
43. Stumvoll M., Goldstein B.J., van Haeften T.W. Type 2 diabetes: pathogenesis and treatment. Lancet 2008, 371:2153-2156.
44. Wofford M.R., Hall J.E. Pathophysiology and treatment of obesity hypertension. Curr Pharm Des 2004, 10:3621-3637.
45. Hajer G.R., Van Haeften T.W., Visseren F.L. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008, 29:2959-2971.
46. Boden G., Lebed B., Schatz M., Homko C., Lemieux S. Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 2001, 50:1612-1617.
47. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850.
48. Ravussin E., Smith S.R. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann N Y Acad Sci 2002, 967:363-378.
49. Lavie C.J., Milani R.V., Ventura H.O. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009, 53:1925-1932.
50. Messerli F.H., Nunez B.D., Ventura H.O., Snyder D.W. Overweight and sudden death. Increased ventricular ectopy in cardiopathy of obesity. Arch Intern Med 1987, 147:1725-1728.
51. Visioli F. Nutritional support in the pharmacological treatment of metabolic syndrome. Eur J Pharmacol 2011, 668:S43-S49.
52. Poulain M., Doucet M., Major G.C., Drapeau V., Sériès F. The effect of obesity on chronic respiratory diseases: pathophysiology and therapeutic strategies. CMAJ 2006, 174:1293-1299.
53. Donohoe C.L., Pidgeon G.P., Lysaght J., Reynolds J.V. Obesity and gastrointestinal cancer. Br J Surg 2010, 97:628-642.
54. Bao B., Wang Z., Li Y., Kong D., Ali S., et al. The complexities of obesity and diabetes with the development and progression of pancreatic cancer. Biochim Biophys Act 2011, 1815:135-146.
55. Xu Q., Anderson D., Lurie-Beck J. The relationship between abdominal obesity and depression in the general population: a systematic review and meta-analysis. Obes Res Clin Pract 2011, 5:e267-e278.
56. Mazza M., Marano G., Traversi G., Bria P., Mazza S. Primary cerebral blood flow deficiency and Alzheimer's disease: shadows and lights. J Alzheimer Dis 2011, 23:375-389.
57. Eisenberg D., Duffy A.J., Bell R.L. Update on obesity surgery. World J astroenterol 2006, 12:3196-3203.
58. Kumanyika S.K., Obarzanek Eva, Stettler N., Bell R., Field A.E., et al. Population-based prevention of obesity: the need for comprehensive promotion of healthful eating, physical activity, and energy balance: a scientific statement from American Heart Association Council on Epidemiology and Prevention, Interdisciplinary Committee for Prevention (formerly the expert panel on population and prevention science). Circulation 2008, 118:428-464.
59. Klein S., Burke L.E., Bray G.A. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, physical activity, and metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004, 110:2954-2967.
60. Rock C.L., Flatt S.W., Sherwood N.E., Karanja N., Pakiz B., et al. Effect of a free prepared meal and incentivized weight loss program on weight loss and weight loss maintenance in obese and overweight women: a randomized controlled trial. JAMA 2010, 304:1803-1810.
61. Anon C. Position of the American Dietetic Association: health implications of dietary fiber. J Am Diet Assoc 1997, 97:1157-1159.
62. Rosenbaum M., Leibel R., Hirsch J. Obesity. N Engl J Med 1997, 337:396-407.
63. http://cals.arizona.edu/pubs/health/az1390.pdf.
64. Spiegelman B.M., Flier J.S. Obesity and the regulation of energy balance. Cell 2001, 104:531-543.
65. Blair S.N., Brodney S. Effects of physical inactivity and obesity on morbidity and mortality: current evidence and research issues. Med Sci Sports Exerc 1999, 31:S646-S662.
66. Stevens J., Evenson K.R., Thomas O., Cai J., Thomas R. Associations of fitness and fatness with mortality in Russian and American men in the lipids research clinics study. Int J Obes Relat Metab Disord 2004, 28:1463-1470.
67. Smith I.G., Goulder M.A. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001, 50:505-512.
68. Rossner S., Sjostrom L., Noack R. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000, 8:49-61.
69. Stafford R.S., Radley D.C. National trends in antiobesity medication use. Arch Intern Med 2003, 163:1046-1050.
70. Li M.F., Cheung B.M. Rise and fall of anti-obesity drugs. World J Diabetes 2011, 2:19-23.
71. Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W. Gilman's AG the pharmacological basis of therapeutics 2008, McGraw-Hill, New York. 9th ed.
72. Lewis W., Elvin-Lewis M. Medical botany, plants affecting man's health 1977, Johan Wiley and Sons Inc., New York.
73. Kissane N.A., Pratt J.S.A. Medical and surgical treatment of obesity. Best Pract Res Clin Anaeshesiol 2011, 25:11-25.
74. Mayer M.A., Hocht C., Puyo A., Taira C.A. Recent advances in obesity pharmacotherapy. Curr Clin Pharmacol 2009, 4:53-61.
75. Han L.K., Kimura Y., Okuda H. Anti-obesity effects of natural products. Stud Nat Prod Chem 2005, 30:79-110.
76. Son M.J., Rico C.W., Nam S.H., Kang M.Y. Influence of oryzanol and ferulic acid on the lipid metabolism and antioxidative status in high fat-fed mice. J Clin Biochem Nutr 2010, 46:150-156.
77. Ramprasath V.R., Jones P.J. Anti-atherogenic effects of resveratrol. Eur J Clin Nutr 2010, 64:660-668.
78. Baile C.A., Yang J.Y., Rayalam S., Hartzell D.L., Lai C.Y., et al. Effect of resveratrol on fat mobilization. Ann N Y Acad Sci 2011, 1215:40-47.
79. Fischer-Posovszky P., Kukulus V., Tews D., Unterkircher T., Debatin K.M., et al. Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. Am J Clin Nutr 2010, 92:5-15.
80. Bureau G., Longpré F., Martinoli M.G. Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. J Neurosci Res 2008, 86:403-410.
81. Nelson-Dooley C., Della-Fera M.A., Hamrick M., Baile C.A. Novel treatments for obesity and osteoporosis: targeting apoptotic pathways in adipocytes. Curr Med Chem 2005, 12:2215-2225.
82. Pongchaidecha A., Lailerd N., Boonprasert W., Chattipakorn N. Effects of curcuminoid supplement on cardiac autonomic status in high-fat-induced obese rats. Nutrition 2009, 25:870-878.
83. Alappat L., Awad A.B. Curcumin and obesity: evidence and mechanisms. Nutr Rev 2010, 68:729-738.
84. Ejaz A., Wu D., Kwan P., Meydani M. Curcumin inhibits adipogenesis in 3T3-L1 adipocytes and angiogenesis and obesity in C57/BL mice. J Nutr 2009, 139:919-925.
85. Aggarwal B.B. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr 2010, 30:173-199.
86. Adlercreutz H. Lignans and human health. Crit Rev Clin Lab Sci 2007, 44:483-525.
87. Ahn J., Lee H., Kima S., Parka J., Taeyoul H. The anti-obesity effect of quercetin is mediated by the AMPK and MAPK signaling pathways. Biochem Biophys Res Commun 2008, 373:545-549.
88. Reyes-Escogido M.L., Gonzalez-Mondragon E.G., Vazquez-Tzompantzi E. Chemical and pharmacological aspects of capsaicin. Molecules 2011, 16:1253-1270.
89. Kang J.H., Tsuyoshi G., Han I.S., Kawada T., Kim Y.M., et al. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet. Obesity 2010, 18:780-787.
90. Kaufinan P., Cseke L., Warber S., Duke J., Brielmann H. Natural products from plants 1999, CRC Press, Boston.
91. Astrup A., Breum L., Toubro S. Pharmacological and clinical studies of ephedrine and other thermogenic agonists. Obes Res 1995, 3:537S-540S.
92. Astrup A., Toubro S., Christensen N., Quade F. Pharmacology of thermogenic drugs. Am J Nutr 1992, 55:246S-248S.
93. Jensen E.X., Fusch C., Jaeger P., Peheim E., Horber F.F. Impact of chronic cigarette smoking on body composition and fuel metabolism. J Clin Endocrinol Metab 1995, 80:2181-2185.
94. Tucci S.A. Phytochemicals in the control of human appetite and body weight. Pharmaceuticals 2010, 3:748-763.
95. Guri A.J., Hontecillas R., Si H., Liu D. Dietary abscisic acid ameliorates glucose tolerance and obesity-related inflammation in db/db mice fed high-fat diets. J Clin Nutr 2007, 26:107-116.
96. Vivekananthan D.P., Penn M.S., Sapp S.K., Hsu A. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003, 361:2017-2023.
97. Agarwal S., Rao A.V. Tomato lycopene and its role in human health and chronic diseases. CMAJ 2000, 163:739-744.
98. Cartea M.E., Velasco P. Glucosinalates is Brasscia foods: bioavailability in food and significance for human health. Phytochem Rev 2008, 7:213-229.
99. Yang J.Y., Della-Fera M.A., Nelson-Dooley C., Baile C.A. Obes Res 2006, 14:388-397.
100. Schonfeld G. Plant sterols in atherosclerosis prevention. Am J Clin Nutr 2010, 92:3-4.
101. Izar M.C., Tegani D.M., Kasmas S.H., Fonseca F.A. Phytosterols and phytosterolemia: gene-diet interactions. Genes Nutr 2011, 6:17-26.
102. Wang T., Choi R.C., Li J., Li J., Bi C.W. Antihyperlipidemic effect of protodioscin, an active ingredient isolated from the rhizomes of Dioscorea nipponica. Planta Med 2010, 76:1642-1646.
103. Uemura T., Goto T., Kang M.S., Mizoguchi N., Hirai S., et al. Diosgenin, the main aglycon of fenugreek, inhibits LXRα activity in HepG2 cells and decreases plasma and hepatic triglycerides in obese diabetic mice. J Nutr 2011, 141:17-23.
104. Ballinger A., Peikin S.R. Orlistat: its current status as an anti-obesity drug. Eur J Pharmacol 2002, 440:109-117.
105. Tsujita T., Takaichi H., Takaku T., Aoyama S., Hiraki J. Antiobesity action of epsilon-polylysine, a potent inhibitor of pancreatic lipase. J Lipid Res 2006, 47:1852-1858.
106. Karamadoukis L., Shivashankar G.H., Ludeman L., Williams A.J. An unusual complication of treatment with orlistat. Clin Nephrol 2009, 71:430-432.
107. Birari R.B., Bhutani K.K. Pancreatic lipase inhibitors from natural sources: unexplored potential. Drug Discov Today 2007, 12:879-889.
108. Shimoda H., Seki E., Aitani M. Inhibitory effect of green coffee bean extract on fat accumulation and body weight gain in mice. BMC Complement Altern Med 2006, 6:9-13.
109. Takao I., Fujii S., Ishii A., Han L.K., Kumao T., et al. Effects of mannooligosaccharides from coffee mannan on fat storage in mice fed a high fat diet. J Health Sci 2006, 52:333-337.
110. Han L.K., Kimura Y., Okuda H. Anti-obesity effects of natural products. Stud Nat Prod Chem 2005, 30:79-110.
111. Mutoh M., Nakada N., Matsukuma S., Ohshima S., Yoshinari K., et al. Panclicins, novel pancreatic lipase inhibitors. I. Taxonomy, fermentation, isolation and biological activity. J Antibiot 1994, 47:1369-1375.
112. Thielecke F., Boschmann M. The potential role of green tea catechins in the prevention of the metabolic syndrome-a review. Phytochemistry 2009, 70:11-24.
113. Gupta J., Siddique Y.H., Beg T., Ara G., Afzal M. A review on the beneficial effects of tea polyphenols on human health. Int J Pharmacol 2008, 4:314-338.
114. Han L.K., Zheng Y.N., Yoshikawa M., Okuda H., Kimura Y. Anti-obesity effects of chikusetsusaponins isolated from Panax japonicus rhizomes. BMC Complement Altern Med 2005, 5:9-14.
115. Han L.K., Takaku T., Li J., Kimura Y., Okuda H. Anti-obesity action of oolong tea. Int J Obes Relat Metab Disord 1999, 23:98-105.
116. Yamamoto M., Shimura S., Itoh Y., Ohsaka T., Egawa M., et al. Anti-obesity effects of lipase inhibitor CT-II, an extract from edible herbs, Nomame Herba, on rats fed a high-fat diet. Int J Obes Relat Metab Disord 2000, 24:758-764.
117. Handa T., Yamaguchi K., Sono Y., Yazawa K. Effects of fenugreek seed extract in obese mice fed a high-fat diet. Biosci Biotechnol Biochem 2005, 69:1186-1188.
118. Han L.K., Sumiyoshi M., Zhang J., Liu M.X., Zhang X.F., et al. Anti-obesity action of Salix matsudana leaves (Part 1). Anti-obesity action by polyphenols of Salix matsudana in high fat-diet treated rodent animals. Phytother Res 2003, 17:1188-1194.
119. Moreno D.A., Ilic N., Poulev A., Brasaemle D.L., Fried S.K., et al. Inhibitory effects of grape seed extract on lipases. Nutrition 2003, 19:876-879.
120. Ninomiya K., Matsuda H., Shimoda H., Nishida N., Kasajima N., et al. Carnosic acid, a new class of lipid absorption inhibitor from sage. Bioorg Med Chem Lett 2004, 14:1943-1946.
121. Hatano T., Yamashita A., Hashimoto T., Ito H., Kubo N., et al. Flavan dimers with lipase inhibitory activity from Cassia nomame. Phytochemistry 1997, 46:893-900.
122. Shimada T., Hiramatsu N., Kasai A., Mukai M., Okamura M., et al. Suppression of adipocyte differentiation by Cordyceps militaris through activation of the aryl hydrocarbon receptor. Am J Physiol Endocrinol Metab 2008, 295:E859-E867.
123. Kawaguchi K., Mizuno T., Aida K., Uchino K. Hesperidin as an inhibitor of lipases from porcine pancreas and Pseudomonas. Biosci Biotechnol Biochem 1997, 61:102-104.
124. Gades M.D., Stern J.S. Chitosan supplementation and fecal fat excretion in men. Obes Res 2003, 11:683-688.
125. Kitahara M., Asano M., Naganawa H., Maeda K., Hamada M., et al. Valilactone, an inhibitor of esterase, produced by actinomycetes. J Antibiot 1987, 40:1647-1650.
126. Garza A.L., Milagro F.I., Boque N., Campión J., Martínez A. Natural inhibitors of pancreatic lipase new players in obesity treatment. Planta Med 2011, 77:773-785.
127. Chantre P., Lairon D. Recent findings of green tea extract AR25 (Exolise) and its activity for the treatment of obesity. Phytomedicine 2002, 9:3-8.
128. Wynne K., Stanley S., McGowan B., Bloom S. Appetite control. J Endocrinol 2005, 184:291-318.
129. Van Heerden F.R. Hoodia gordonii: a natural appetite suppressant. J Ethnopharmacol 2008, 119:434-437.
130. Ohia S.E., Opere C.A., LeDay A.M., Bagchi M., Bagchi D., et al. Safety and mechanism of appetite suppression by a novel hydroxycitric acid extract (HCA-SX). Mol Cell Biochem 2002, 238:89-103.
131. Husain G.M., Chatterjee S.S., Singh P.N., Kumar V. Hypolipidemic and antiobesity-like activity of standardized extract of Hypericum perforatum L. in rats. Int Scholarly Res Network Pharmacol 2011, article ID 505247:1-7.
132. Kim J.H., Hahm D.H., Yang D.C., Kim J.H., Lee H.J., et al. Effect of crude saponin of Korean red ginseng on high-fat diet-induced obesity in the rat. J Pharmacol Sci 2005, 97:124-131.
133. Saito M., Ueno M., Ogino S., Kubo K., Nagata J., et al. High dose of Garcinia cambogia is effective in suppressing fat accumulation in developing male Zucker obese rats, but highly toxic to the testis. Food Chem Toxicol 2005, 43:411-419.
134. Moon H.S., Lee H.G., Choi Y.J., Kim T.G., Cho C.S. Proposed mechanisms of (-)-epigallocatechin-3-gallate for anti-obesity. Chem Biol Interact 2007, 167:85-98.
135. MacLean D.B., Luo L.G. Increased ATP content/production in the hypothalamus may be a signal for energy-sensing of satiety: studies of the anorectic mechanism of a plant steroidal glycoside. Brain Res 2004, 1020:1-11.
136. Baintner K., Kiss P., Pfüller U., Bardocz S., Pusztai A. Effect of orally and intraperitoneally administered plant lectins on food consumption of rats. Acta Physiol Hung 2003, 90:97-107.
137. Hughes G.M., Boyland E.J., Williams N.J., Mennen L., Scott C., et al. The effect of Korean pine nut oil (PinnoThin) on food intake, feeding behaviour and appetite: a double-blind placebo-controlled trial. Lipids Health Dis 2008, 7:1-10.
138. Fleming R.M. The effect of ephedra and high fat dieting: a cause for concern! A case report. Angiology 2007, 58:102-105.
139. Klontz K.C., Timbo B.B., Street D. Consumption of dietary supplements containing Citrus aurantium (bitter orange)-2004 California Behavioral Risk Factor Surveillance Survey (BRFSS). Ann Pharmacother 2006, 40:1747-1751.
140. Redinger R.N. Fat storage and the biology of energy expenditure. Transl Res 2009, 154:52-60.
141. Cannon B., Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev 2004, 84:277-359.
142. Yoon S.S., Rhee Y.H., Lee H.J., Lee E.O., Lee M.H., et al. Uncoupled protein 3 and p38 signal pathways are involved in anti-obesity activity of Solanum tuberosum L. cv. Bora Valley. J Ethnopharmacol 2008, 118:396-404.
143. Rayalam S., Della-Fera M.A., Baile C.A. Phytochemicals and regulation of the adipocyte life cycle. J Nutr Biochem 2008, 19:717-726.
144. Kim H.K., Della-Fera M., Lin J., Baile C.A. Docosahexaenoic acid inhibits adipocyte differentiation and induces apoptosis in 3T3-L1 preadipocytes. J Nutr 2006, 136:2965-2969.
145. Awad A.B., Begdache L.A., Fink C.S. Effect of sterols and fatty acids on growth and triglyceride accumulation in 3T3-L1 cells. J Nutr Biochem 2000, 11:153-158.
146. Madsen L., Petersen R.K., Kristiansen K. Regulation of adipocyte differentiation and function by polyunsaturated fatty acids. Biochim Biophys Acta 2005, 1740:266-286.
147. Yang J.Y., Della-Fera M.A., Hartzell D.L., Nelson-Dooley C., Hausman D.B., et al. Esculetin induces apoptosis and inhibits adipogenesis in 3T3-L1 cells. Obesity 2006, 14:1691-1699.
148. Kim M.S., Kim J.K., Kwon D.Y., Park R. Anti-adipogenic effects of Garcinia extract on the lipid droplet accumulation and the expression of transcription factor. Biofactors 2004, 22:193-196.
149. Naaz A., Yellayi S., Zakroczymski M.A., Bunick D., Doerge D.R., et al. The soy isoflavone genistein decreases adipose deposition in mice. Endocrinology 2003, 144:3315-3320.
150. Hsu H.K., Yang Y.C., Hwang J.H., Hong S.J. Effects of Toona sinensis leaf extract on lipolysis in differentiated 3T3-L1 adipocytes. Kaohsiung J Med Sci 2003, 19:385-390.
151. Kim H.J., Takahashi M., Ezaki O. Fish oil feeding decreases mature sterol regulatory element-binding protein 1 (SREBP-1) by down-regulation of SREBP-1c mRNA in mouse liver. A possible mechanism for down-regulation of lipogenic enzyme mRNAs. J Biol Chem 1999, 274:25892-25898.
152. Uto-Kondo H., Ohmori R., Kiyose C., Kishimoto Y., Saito H., et al. Tocotrienol suppresses adipocyte differentiation and Akt phosphorylation in 3T3-L1 preadipocytes. J Nutr 2009, 139:51-57.
153. Ku H.C., Chang H.H., Liu H.C., Hsiao C.H., Lee M.J., et al. Green tea (-)-epigallocatechin gallate inhibits insulin stimulation of 3T3-L1 preadipocyte mitogenesis via the 67-kDa laminin receptor pathway. Am J Physiol Cell Physiol 2009, 297(1):C121-C132.
154. Hwang J.T., Lee M.S., Kim H.J., Sung M.J., Kim H.Y., et al. Antiobesity effect of ginsenoside Rg3 involves the AMPK and PPAR-gamma signal pathways. Phytother Res 2009, 23:262-266.
155. Ka S.O., Kim K.A., Kwon K.B., Park J.W., Park B.H. Silibinin attenuates adipogenesis in 3T3-L1 preadipocytes through a potential upregulation of the insig pathway. Int J Mol Med 2009, 23:633-637.
156. Ambati S., Yang J.Y., Rayalam S., Park H.J., Della-Fera M.A., et al. Ajoene exerts potent effects in 3T3-L1 adipocytes by inhibiting adipogenesis and inducing apoptosis. Phytother Res 2009, 23:513-518.
157. Takahashi T., Tabuchi T., Tamaki Y., Kosaka K., Takikawa Y., et al. Carnosic acid and carnosol inhibit adipocyte differentiation in mouse 3T3-L1 cells through induction of phase2 enzymes and activation of glutathione metabolism. Biochem Biophys Res Commun 2009, 382:549-554.
158. Ejaz A., Wu D., Kwan P., Meydani M. Curcumin inhibits adipogenesis in 3T3-L1 adipocytes and angiogenesis and obesity in C57/BL mice. J Nutr 2009, 139:919-925.
159. Yang J.Y., Della-Fera M.A., Rayalam S., Baile C.A. Effect of xanthohumol and isoxanthohumol on 3T3-L1 cell apoptosis and adipogenesis. Apoptosis 2007, 12:1953-1963.
160. Ohkoshi E., Miyazaki H., Shindo K., Watanabe H., Yoshida A., et al. Constituents from the leaves of Nelumbo nucifera stimulate lipolysis in the white adipose tissue of mice. Planta Med 2007, 73:1255-1259.
161. Lee J., Chae K., Ha J., Park B.Y., Lee H.S., et al. Regulation of obesity and lipid disorders by herbal extracts from Morus alba, Melissa officinalis, and Artemisia capillaris in high-fat diet-induced obese mice. J Ethnopharmacol 2008, 115:263-270.
162. Weisberg S.P., Leibel R., Tortoriello D.V. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology 2008, 149:3549-3558.
163. Birari R.B., Gupta S., Mohan G., Bhutani K.K. Antiobesity and lipid lowering effects of Glycyrrhiza chalcones: experimental and computational studies. Phytomedicine 2011, 18:795-801.
164. Park M.Y., Lee K.S., Sung M.K. Effects of dietary mulberry, Korean red ginseng, and banaba on glucose homeostasis in relation to PPAR-alpha, PPAR-gamma, and LPL mRNA expressions. Life Sci 2005, 77:3344-3354.
165. Tsuda T., Horio F., Uchida K., Aoki H., Osawa T. Dietary cyanidin 3-O-beta-d-glucoside-rich purple corn color prevents obesity and ameliorates hyperglycemia in mice. J Nutr 2003, 133:2125-2130.
166. Yang J.Y., Lee S.J., Park H.W., Cha Y.S. Effect of genistein with carnitine administration on lipid parameters and obesity in C57Bl/6J mice fed a high-fat diet. J Med Food 2006, 9:459-467.
167. Duke J. Advance praise for the green pharmacy 1997, Rodale Press, Pennsyvanian.
168. Lei F., Zhang X.N., Wang W., Xing D.M., Xie W.D., et al. Evidence of anti-obesity effects of the pomegranate leaf extract in high-fat diet induced obese mice. Int J Obes 2007, 31:1023-1029.
169. Moreno D.A., Ilic N., Poulev A., Raskin I. Effects of Arachis hypogaea nutshell extract on lipid metabolic enzymes and obesity parameters. Life Sci 2006, 78:2797-2803.
170. Tsi D., Das N., Tan B. Effects of aqueous celery (Apium graveolens) extract on lipid parameters of rats fed a high fat diet. Planta Med 1995, 61:18-21.
171. Mahmoud R.H., Elnour W.A. Comparative evaluation of the efficacy of ginger and orlistat on obesity management, pancreatic lipase and liver peroxisomal catalase enzyme in male albino rats. Eur Rev Med Pharmacol Sci 2013, 17:75-83.
172. Selvendran R.R. The plant cell wall as a source of dietary fiber: chemistry and structure. Am J Clin Nutr 1984, 39:320-337.
173. Rang H.P., Dale M.M., Ritter J.M., Flower R.J. Rang and Dale's pharmacology 2007, McGraw-Hill, New York. 6th ed.
174. Di-lorenzo C., Williams C., Hainal F., Valenzuela J. Pectin delays gastric emptying and increases satiety in obese subjects. Gastroenterology 1988, 95:1211-1215.
175. Frati-Munari A., Fernandez J., Becerril M., Chavez A., Banles M. Decrease in serum lipids, glycemia and body weight by Plantago psyllium in obese and diabetic patients. Arch Invest Med 1983, 14:259-268.
176. Evans W. Trease and Evan's pharmacognosy 1996, WB Sunders Company Ltd., London. 40th ed.
177. Desmet P., Keller K., Hansel R., Chandler R. Adverse effects of herbal drugs 2 1993, Spriger-Verlag, Berlin.
178. Leite-Silva C., Gusmão C.L.S., Takahashi C.S. Genotoxic and antigenotoxic effects of Fucus vesiculosus extract on cultured human lymphocytes using the chromosome aberration and Comet assays. Genet Mol Biol 2007, 30:105-111.
179. Chojnacka K., Saeid A., Witkowska Z., Tuhy L. Biologically active compounds in seaweed extracts-the prospects for the application. Open Conf Proceed J 2012, 3:20-28.
180. Maeda H., Hosokawa M., Sashima T., Funayama K., Miyashita K. Fucoxanthin from edible seaweed, Undaria pinnatifida, shows antiobesity effect through UCP1 expression in white adipose tissues. Biochem Biophys Res Commun 2005, 332:392-397.
181. Peng J., Yuan J., Wu C., Wang J. Fucoxanthin, a marine carotenoid present in brown seaweeds and diatoms: metabolism and bioactivities relevant to human health. Mar Drugs 2011, 9:1806-1828.
182. Miyashita K. Anti-obesity therapy by food component: unique activity of marine carotenoid, fucoxanthin. Obes Control Ther 2014, 1:1-4.
183. Wang H., Fu Z., Han C. The potential applications of marine bioactives against diabetes and obesity. Am J Mar Sci 2014, 2:1-8.
184. Bunea R., El Farrah K., Deutsch L. Evaluation of the effects of neptune krill oil on the clinical course of hyperlipidemia. Altern Med Rev 2004, 9:420-428.
185. Maki K.C., Reeves M.S., Farmer M., Griinari M., Berge K., et al. Krill oil supplementation increases plasma concentrations of eicosapentaenoic and docosahexaenoic acids in overweight and obese men and women. Nutr Res 2009, 29:609-615.